Isocitrate dehydrogenase [NADP] cytoplasmic · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Isocitrate dehydrogenase [NADP] cytoplasmic shows approved-linked disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt O75874. Start with acute myeloid leukemia, then reuse UniProt O75874 as the stable protein anchor across project notes and exports.
Start with acute myeloid leukemia, then reuse UniProt O75874 as the stable protein anchor across project notes and exports.
Isocitrate dehydrogenase [NADP] cytoplasmic shows approved-linked disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block. 4 linked drugs remain visible in the same block.
Start review with acute myeloid leukemia because it currently carries approved-linked support. Linked drugs include BAY1436032, IDH305, IVOSIDENIB, OLUTASIDENIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyIsocitrate dehydrogenase [NADP] cytoplasmic
Review this target as Isocitrate dehydrogenase [NADP] cytoplasmic, mapped to UniProt O75874. Sequence length is 414 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Isocitrate dehydrogenase [NADP] cytoplasmic as ChEMBL target CHEMBL2007625, mapped to UniProt O75874. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Isocitrate dehydrogenase [NADP] cytoplasmic is the right protein anchor across sources, using UniProt O75874 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why acute myeloid leukemia is currently framed as approved-linked support. It currently carries 4 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Isocitrate dehydrogenase [NADP] cytoplasmic |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | O75874 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Isocitrate dehydrogenase [NADP] cytoplasmic |
| UniProt Accession | O75874 |
| Component Type | Protein |
| Sequence Length | 414 aa |
Isocitrate dehydrogenase [NADP] cytoplasmic
Review this target as Isocitrate dehydrogenase [NADP] cytoplasmic, mapped to UniProt O75874. Sequence length is 414 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Isocitrate dehydrogenase [NADP] cytoplasmic shows approved-linked disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block.
Start review with acute myeloid leukemia because it currently carries approved-linked support. Linked drugs include BAY1436032, IDH305, IVOSIDENIB, OLUTASIDENIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4279047 | 10.4 | IC50 | 0.04 | Approved |
| CHEMBL4278845 | 9.6 | IC50 | 0.25 | Preclinical |
| CHEMBL4283785 | 9.52 | IC50 | 0.3 | Preclinical |
| CHEMBL5633097 | 9.46 | IC50 | 0.349 | Preclinical |
| CHEMBL4448475 | 9.37 | EC50 | 0.43 | Preclinical |
| CHEMBL4280132 | 9.15 | IC50 | 0.7 | Preclinical |
| CHEMBL4280772 | 9.0 | IC50 | 1.0 | Preclinical |
| CHEMBL4278793 | 9.0 | IC50 | 1.0 | Preclinical |
| CHEMBL4277352 | 9.0 | IC50 | 1.0 | Preclinical |
| CHEMBL3909586 | 9.0 | IC50 | 1.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 187 | 3,644 | 6.5 |
| cell-based format | 178 | 491 | 6.8 |
| assay format | 103 | 533 | 6.8 |
| subcellular format | 1 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| organism-based format | 7 | 0 | — |
| assay format | 4 | 0 | — |
| cell-based format | 1 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 1 | 1 | 5.2 |